- 3. Special items
- 4. Sales
- 5. Cost of sales
- 6. Cost of materials
- 7. Personnel expenses
- 8. Selling, general and administrative expenses
- 9. Investment gain
- 10. Net interest
- 11. Other financial result
- 12. Taxes
- 13. Earnings per share
12. Taxes
Income taxes
Income before income taxes was attributable to the following geographic regions:
€ in millions | 2012 | 2011 |
---|---|---|
Germany | 414 | 404 |
International | 1,977 | 1,528 |
Total | 2,391 | 1,932 |
Income tax expenses (benefits) for 2012 and 2011 consisted of the following:
€ in millions | Current taxes | Deferred taxes | Income taxes |
---|---|---|---|
2012 | |||
Germany | 82 | -17 | 65 |
International | 599 | -5 | 594 |
Total | 681 | -22 | 659 |
2011 | |||
Germany | 96 | 9 | 105 |
International | 427 | 72 | 499 |
Total | 523 | 81 | 604 |
In 2012 and 2011, Fresenius SE & Co. KGaA was subject to German federal corporation income tax at a base rate of 15% plus a solidarity surcharge of 5.5% on federal corporation taxes payable.
A reconciliation between the expected and actual income tax expense is shown in the following table. The expected corporate income tax expense is computed by applying the German corporation tax rate (including the solidarity surcharge) and the effective trade tax rate on income before income taxes. The respective combined tax rate was 29.5% for the fiscal year 2012 (2011: 29.0%).
€ in millions | 2012 | 2011 |
---|---|---|
Computed “expected” income tax expense | 705 | 560 |
Increase (reduction) in income taxes resulting from: | ||
Items not recognized for tax purposes | 18 | 12 |
Tax rate differential | 37 | 56 |
Tax-free income | -64 | -12 |
Taxes for prior years | 21 | 4 |
Changes in valuation allowances on deferred tax assets | -20 | 5 |
Noncontrolling interests | -38 | -22 |
Other | - | 1 |
Income tax | 659 | 604 |
Effective tax rate | 27.6% | 31.3% |
Deferred taxes
The tax effects of the temporary differences that gave rise to deferred tax assets and liabilities at December 31 are presented below:
€ in millions | 2012 | 2011 |
---|---|---|
Deferred tax assets | ||
Accounts receivable | 16 | 14 |
Inventories | 96 | 79 |
Other current assets | 74 | 93 |
Other non-current assets | 145 | 127 |
Accrued expenses | 251 | 183 |
Other short-term liabilities | 64 | 86 |
Other liabilities | 36 | 28 |
Benefit obligations | 139 | 92 |
Losses carried forward from prior years | 253 | 151 |
Deferred tax assets, before valuation allowance | 1,074 | 853 |
less valuation allowance | 101 | 121 |
Deferred tax assets | 973 | 732 |
Deferred tax liabilities | ||
Accounts receivable | 15 | 23 |
Inventories | 22 | 22 |
Other current assets | 16 | 11 |
Other non-current assets | 736 | 560 |
Accrued expenses | 120 | 23 |
Other short-term liabilities | 50 | 123 |
Other liabilities | 103 | 102 |
Deferred tax liabilities | 1,062 | 864 |
Net deferred taxes | -89 | -132 |
In the consolidated statement of financial position, the net amounts of deferred tax assets and liabilities are included as follows:
2012 | 2011 | |||
---|---|---|---|---|
€ in millions | thereof short-term |
thereof short-term |
||
Deferred tax assets | 659 | 401 | 493 | 368 |
Deferred tax liabilities | 748 | 66 | 625 | 52 |
Net deferred taxes | -89 | 335 | -132 | 316 |
As of December 31, 2012, Fresenius Medical Care has not recognized a deferred tax liability on approximately €4.2 billion of undistributed earnings of its foreign subsidiaries, because those earnings are intended to be indefinitely reinvested.
Net operating losses
The expiration of net operating losses is as follows:
for the fiscal years | € in millions |
---|---|
2013 | 17 |
2014 | 21 |
2015 | 23 |
2016 | 27 |
2017 | 48 |
2018 | 21 |
2019 | 20 |
2020 | 13 |
2021 | 10 |
2022 and thereafter | 124 |
Total | 324 |
The total remaining operating losses of €347 million can mainly be carried forward for an unlimited period.
Based upon the level of historical taxable income and projections for future taxable income, the Management of the Fresenius Group believes it is more likely than not that the Fresenius Group will realize the benefits of these deductible differences, net of the existing valuation allowances, at December 31, 2012.
Unrecognized tax benefits
Fresenius SE & Co. KGaA and its subsidiaries are subject to tax audits in Germany and the United States on a regular basis and ongoing tax audits in other jurisdictions.
In Germany, the tax years 2002 to 2009 are currently under audit by the tax authorities. The Fresenius Group recognized and recorded the current proposed adjustments of this audit period in the consolidated financial statements. All proposed adjustments are deemed immaterial. Fiscal years 2010, 2011 and 2012 are open to audit.
In the United States, Fresenius Medical Care filed claims for refunds contesting the Internal Revenue Service’s (IRS) disallowance of Fresenius Medical Care Holdings, Inc.’s (FMCH) civil settlement payment deductions taken by FMCH in prior year tax returns. As a result of a settlement agreement with the IRS, Fresenius Medical Care received a partial refund in September 2008 of US$37 million, inclusive of interest, and preserved its right to pursue claims in the United States Courts for refunds of all other disallowed deductions, which totaled approximately US$126 million. On December 22, 2008, Fresenius Medical Care filed a complaint for complete refund in the United States District Court for the District of Massachusetts, styled as Fresenius Medical Care Holdings, Inc. v. United States. On August 15, 2012, a jury entered a verdict for FMCH granting additional deductions of US$95 million. The District Court is now considering post trial motions by the IRS to set aside the verdict and the terms of the judgment to be entered against the United States to reflect the amount of the tax refund due to FMCH.
In the United States, the tax years 2009 and 2010 are currently under audit by the tax authorities. Fiscal years 2011 and 2012 are open to audit. FMCH is also subject to audit in various state jurisdictions. A number of these audits are in progress and various years are open to audit in various state jurisdictions. All expected results for both federal and state income tax audits have been recognized in the consolidated financial statements.
Subsidiaries of Fresenius SE & Co. KGaA in a number of countries outside of Germany and the United States are also subject to tax audits. The Fresenius Group estimates that the effects of such tax audits are not material to these consolidated financial statements.
The following table shows the changes to unrecognized tax benefits during the year 2012:
€ in millions | 2012 |
---|---|
Balance at January 1, 2012 | 224 |
Increase in unrecognized tax benefits prior periods | 42 |
Decrease in unrecognized tax benefits prior periods | -6 |
Increase in unrecognized tax benefits current periods | 17 |
Changes related to settlements with tax authorities | -13 |
Reductions as a result of a lapse of the statute of limitations | -2 |
Foreign currency translation | -10 |
Balance at December 31, 2012 | 252 |
Included in the balance at December 31, 2012 are €234 million of unrecognized tax benefits, which would affect the effective tax rate if recognized. The Fresenius Group is currently not in a position to forecast the timing and magnitude of changes in other unrecognized tax benefits.
It is Fresenius Group’s policy to recognize interest and penalties related to its tax positions as income tax expense. During the fiscal year 2012, the Fresenius Group recognized €2 million in interest and penalties. The Fresenius Group had a total accrual of €29 million of tax related interest and penalties at December 31, 2012.
11. Other financial result
13. Earnings per share